Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targanta Files Oritavancin NDA For cSSSI, Aiming To Tackle Vancomycin Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Third owner of Lilly-developed compound touts antibiotic’s shorter course of treatment and dosing advantages over competing therapies.

You may also be interested in...



Targanta’s Oritavacin Faces Statistical Hurdle At Advisory Committee

FDA is asking the Anti-Infective Drugs Advisory Committee to review the choice confidence interval in Targanta’s studies for the antibiotic oritavancin.

Targanta’s Oritavacin Faces Statistical Hurdle At Advisory Committee

FDA is asking the Anti-Infective Drugs Advisory Committee to review the choice confidence interval in Targanta’s studies for the antibiotic oritavancin.

As Cubicin Threats Line Up, Cubist Spells Out A Strategy

Firm seeks new indications, late-stage assets.

Related Content

Topics

UsernamePublicRestriction

Register

PS067228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel